Expansion cohorts in first-in-human solid tumor oncology trials

Clinical Cancer Research

Volumn 21, Issue 20, 2015, Pages 4545-4551

  Theoret, Marc R ^a   Pai Scherf, Lee H ^a   Chuk, Meredith K ^a   Prowell, Tatiana M ^a   Balasubramaniam, Sanjeeve ^a   Kim, Tamy ^a   Kim, Geoffrey ^a   Kluetz, Paul G ^a   Keegan, Patricia ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IPILIMUMAB; PEMBROLIZUMAB; PLACEBO; NEW DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY CARCINOMA; MELANOMA; ONCOLOGY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SAMPLE SIZE; SOLID TUMOR; NEOPLASMS; PROCEDURES; UNITED STATES;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84945542507     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3244     Document Type: Article

References (14)

1. Manji A, Brana E, Amir E, Tomlinson G, Tannock IF, Beddard PL, et al. Evolution of clinical trial design in early drug development: systemic review of expansion cohort use in single-agent phase I cancer trials. J Clin Oncol 2013;31:4260-7.
2. Dienstmann R, Rodon J, Barretina J, Tabernero J. Genomic medicine frontier in human solid tumors: prospects and challenges. J Clin Oncol 2013;31:1874-84.
3. Chen SD, Melman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1-10.
4. McDermott U, Downing JR, Stratton MR. Genomics and the continuum of cancer care. N Engl J Med 2011;364:340-50.
5. ICHharmonised tripartite guideline: general considerations for clinical trials (E8) [PDF on the Internet]. Geneva (Switzerland): The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH); 1997 [cited 2015 Aug 12]. Available from: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E8/Step4/E8-Guideline.pdf.
6. Temple R. Current definitions of phases of investigation and the role of the FDA in the conduct of clinical trials. Am Heart J 2000;139: S133-5.
7. Guidance for industry: postmarketing studies and clinical trials - implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act [PDF onthe Internet]. Silver Spring(MD):U.S. FoodandDrugAdministration;2011 [cited 2015 Aug 12]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm172001.pdf.
8. Dahlberg SE, Shapiro GI, Clark JW, Johnson BE. Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience. J Natl Cancer Inst 2014;106:1-7.
9. Guidance for industry: expedited programs for serious conditions-drugs and biologics [PDF on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2014 [cited 2015 Aug 12]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf.
10. Good review practice: management of Breakthrough Therapy-designated drugs and biologics [PDF on the Internet]. In: Manual of policies and procedure, Center forDrug Evaluation and Research (MAPP6025.6). Silver Spring (MD): U.S. Food and Drug Administration, Office of New Drugs; 2014 [cited 2015 Aug 1]. Available from: http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ManualofPoliciesProcedures/UCM407009.pdf.
11. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-17.
12. Drugs@FDA [database on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2014[cited 2015Aug 1]. Summary review; reference ID: 3621254 [about 22 p.]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2014/125514Orig1s000SumR.pdf. Files updated daily.
13. Guidance for clinical trial sponsors: establishment and operation of clinical trial data monitoring committees [PDF on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2006 [cited 2015 Aug 1]. Available from: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf.
14. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28.